Biopharma teams don’t lose because they lack ambition. They lose because the calendar is misaligned.
In licensing, partnering, and BD strategy, timing is everything—yet one of the most overlooked levers is sitting in plain sight: packaging. Specificall…
Generic drugs are supposed to be boring. Until you look at the business models.
The latest DrugPatentWatch piece on “two roads to generic drug profits”—the U.S. niche strategy versus India’s mass-market model—lands on a truth that investors, operator…
Two Roads to Generic Drug Profits: The US Niche Strategy vs. India’s Mass Market Model Read Post »
Big Pharma doesn’t just “lose” patents—it often rebrands the battlefield.
That’s the core takeaway from DrugPatentWatch’s look at what happens after exclusivity ends: the branded-generic playbook. In plain English, when a patent cliff approaches, the i…
After the Patent: Big Pharma’s Branded Generic Playbook Read Post »
In the high-stakes world of pharmaceuticals, innovation is often viewed through the lens of new drug development, hefty R&D budgets, and regulatory hurdles. But what if the real treasure trove lies not in the next big blockbuster, but in the overlo…
Expired and Abandoned Drug Patents: The Hidden Goldmine Everyone Ignores Read Post »
In the high-stakes world of biopharma, timing isn’t just everything—it’s the difference between riding a wave of growth or being left behind as the tide recedes. As the industry faces mounting pressures—from patent cliffs to accelerating innovation—equ…
Sell Before the Cliff Drops: A BD Playbook for Biopharma Equipment Suppliers Read Post »
In the fast-paced world of pharmaceuticals, timing is everything. When a blockbuster drug’s patent expires, it opens the floodgates for generic competition, dramatically altering market dynamics and profit margins. Yet, for many pharma executives and i…
Track Global Drug Patent Expiry by Geography — Without Hiring a Team of Analysts Read Post »
The Coming Wave of Patent Cliffs: Is Your Pharma Manufacturing Ready for the Next Disruption?
In the high-stakes world of pharmaceutical manufacturing, innovation isn’t just about developing new drugs—it’s about staying ahead of the patent cliff that t…
Drug Patent Cliffs Tell You Who Needs a New Tablet Press Read Post »
The Hidden Truth About Drug Patents: Why Your Assumptions Could Be Costing You Millions
Imagine investing millions into a groundbreaking pharmaceutical, only to find out that your patent protection isn’t as ironclad as you believed. It’s a scenario tha…
In the high-stakes world of biopharmaceutical innovation, timing isn’t just everything—it’s the difference between market leadership and missed opportunities. Yet, despite the rapid pace of drug development and approval, many biopharma companies remain…
ð¨ The Hidden Pitfall in Patent Law That Could Cost Pharma Billions — And It’s Already Happening ð¨
Imagine pouring millions into developing a groundbreaking drug, only to see your patent extension denied at the eleventh hour — not because of the i…
PTE Denied: The Rules That Kill Patent Term Extensions Before They Start Read Post »